Transcription of Public Assessment Report Mutual Recognition …
{{id}} {{{paragraph}}}
Example: stock market
Public Assessment Report Mutual Recognition …
PAR Sayana 104 Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104 SUSPENSION FOR INJECTION UK/H/0960/001/MR UK licence no: PL 00057/0589 Pfizer Limited PAR Sayana 104 Suspension for Injection UK/H/0960/001/MR 2 SAYANA 104 SUSPENSION FOR INJECTION LAY SUMMARY On 9th July 2007, Austria, Belgium, Czech Republic, Germany, Hungary, Ireland, The Netherlands, Norway and Poland granted Marketing Authorisations to Pfizer Limited for the medicinal product Sayana 104 Suspension for Injection. The licences were granted by Mutual Recognition Procedure (MRP), with the UK as Reference Member State (RMS). A licence had previously been granted in the UK on 26th October 2005.
PAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PROVERA Medroxyprogesterone acetate, PROVERA ® Medroxyprogesterone acetate, Medroxyprogesterone acetate, USPI medroxyprogesterone acetate - Depo, Medroxyprogesterone, Product List – 2010, Sayanaject 104 mg suspension for, Suspension for injection medroxyprogesterone acetate Single-dose, Approved Prescription Products for Menopausal, Pfizer